Clarithromycin Impurity G is a degradation byproduct arising from hydrolytic cleavage of the amide linkage between the clindamycin-derived side chain and the 14-membered erythronolide lactone core. This impurity features a partially hydrolyzed lactone ring with a residual hydroxyl group at C-9 and a deaminated side chain bearing a terminal carboxylic acid. Structural analysis confirms retention of the macrocyclic framework with loss of the methyl ester functionality characteristic of the parent drug. This compound serves as an HPLC reference standard for quantifying process-related degradation in clarithromycin formulations.
On Request127252-80-6
CC[C@@H]1[C@@]([C@@H]([C@H](/C(=N/OC)/[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O
InChI=1S/C39H72N2O13/c1-16-27-39(10,46)32(43)22(4)29(40-49-15)20(2)18-38(9,48-14)34(54-36-30(42)26(41(11)12)17-21(3)50-36)23(5)31(24(6)35(45)52-27)53-28-19-37(8,47-13)33(44)25(7)51-28/h20-28,30-34,36,42-44,46H,16-19H2,1-15H3/b40-29+/t20-,21-,22+,23+,24-,25+,26+,27-,28+,30-,31+,32-,33+,34-,36+,37-,38-,39-/m1/s1
BZXVFUGKJGEBBE-HQQTWTRQSA-N